Podcasts about aldeyra

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Sanofi and Alnylam have received FDA approval for the first RNAi treatment for hemophilia, with the drug, Qfitlia, indicated for both hemophilia A and B. This approval is significant as it can be given regardless of the presence of neutralizing antibodies against clotting factors VIII or IX. However, the sudden departure of FDA director Peter Marks has caused uncertainty in the biopharma industry. In other news, Vertex has cut a diabetes asset but analysts remain optimistic about their phase III option. Lilly's RNA silencer has shown promising results in lowering a key cardiovascular biomarker. Trilink is offering custom guide RNAs for CRISPR workflow to accelerate therapy discoveries. Despite market challenges, the cell and gene therapy sector has seen a 30% investment surge. Companies like Amgen, Aldeyra, and Argenx are among those with upcoming FDA actions. Arbutus has announced layoffs, while big pharmas are pushing boundaries in radiopharmaceuticals. Michelle Werner of AltoRNA is focused on making better drugs. Safety questions are looming in Duchenne as Dyne and Wave plan FDA filings. There are job opportunities available in data management and program leadership within the biopharma industry.Moving on to other news, several big pharmaceutical companies such as Novartis, Bayer, AstraZeneca, Bristol Myers Squibb, and Eli Lilly are competing in the radiopharmaceuticals market, which is projected to be worth over $13 billion by 2033. The FDA is expected to announce decisions on therapies for dry eye disease soon. Michelle Werner, CEO of AllTrna, is focused on developing trna-based treatments for various diseases.Safety concerns are emerging in the Duchenne muscular dystrophy space as companies like Dyne and Wave plan FDA filings. The EU rejected Lilly's Alzheimer's drug Kisunla, Biontech's bispecific showed promise in treating SCLC patients, and Wave's duchenne exon-skipper reversed muscle damage in a mid-stage trial. Job opportunities within the biopharma industry were also highlighted for those interested.Thank you for tuning in to Pharma and Biotech daily - keeping you updated on all the latest news in the world of pharmaceuticals and biotechnology.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news stories, live from Hawaiian Eye. Welcome to the Eyeluminaries podcast :01 Review of episode 10, the Allergan alumni guests 1:30 Bausch + Lomb announces acquisition of AcuFocus 3:39 Mazzo attributes success to people and the magic of ophthalmology 5:40 Keranova's PhotoEmulsification technique shows promising results 9:25 Centricity CEO discusses latest cataract surgery products 11:04 Orasis submits new drug application for presbyopia drop 12:30 Aldeyra submits NDA for primary vitreoretinal lymphoma treatment 15:27 Iveric Bio submits final part of Zimura new drug application for rolling review 17:30 Tom Frinzi to become CEO of STAAR Surgical 22:37 Wrap up and a preview of episode 12 25:38 Feedback, questions and guest suggestions at eyeluminaries@healio.com 27:39 Thanks for listening 28:00 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

A Rare Clinical Research Perspective from Both Sides of the Fence It's uncommon to see those in the clinical research profession move from site-based roles to sponsor-based roles - or vice versa. In this episode, Adrienne Gaggi, Associate Director of Clinical Development at Aldeyra Therapeutics, shares her thoughts on hot topics around clinical research. Adrienne gives her comprehensive, expert opinion about patient enrollment, sites, and sponsors' roles, as well as the different challenges faced, and tactics used to meet the studies' needs. Tune in and listen to what Adrienne Gaggi says about the current Clinical Trial Space and her take on some of its critical operational issues! Click this link to the show notes, transcript, and resources: outcomesrocket.health

Heute geht es um die Aktien von Aldeyra Therapeutics, PAION und ElringKlinger.

No – not that apprentice. This week we had the pleasure of speaking with Todd Brady, MD/PhD turned VC/EIR turned CEO of Aldeyra back in 2012. Todd talks about how he transitioned from the lab over to the dark side back in the 90s when “Industry” was still a dirty word. Todd found his calling as a company builder who has since taken Aldeyra public and into Phase 3 trials with novel treatments for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. The company is also developing other product candidates for retinal and systemic inflammatory diseases. Listen in for some words of wisdom from the real Apprentice…

In this episode, John S. Pollack, MD, discusses how he got started with the American Society of Retina Specialists, gives the scoop on the PAT survey and provides career advice for young retina specialists. Intro :15 In this episode :18 About Dr. Pollack :24 The interview :45 Who is Dr. Pollack? 1:10 What’s your favorite part about the field of retina? 2:37 How did you get involved with the ASRS? 3:58 Who write the questions for the PAT survey? 5:54 How should community retina specialists utilize and view the PAT survey? 7:04 Are you currently taking responses? 7:50 What are the top issues ASRS will be dealing with this year? 8:12 Indications for surgery for epiretinal membranes: visual acuity or visual function? 8:50 What will have the biggest impact on retina for years to come? 15:28 Career advice for young retina specialists; academic vs. private practice? 18:49 Do you factor health care policy/reform into this decision? In 5 years, will health care be the same? 21:32 The Winning Pitch Challenge 22:51 How an idea in clinic turned into a product 26:45 Thanks for listening! 28:00 John S. Pollack, MD, is past president of the American Society of Retina Specialists; partner at Illinois Retina Associates, Rush University Medical Center in Chicago. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Pollack reports grant/research support from Aldeyra; consulting for Allergan, Dutch Ophthalmic Research Company, Graybug, Regeneron, REGENXBIO and Santen; founder and stock at Covalent Medical; grant support and consulting from Genentech; BOD, stock and consultant for Notal Vision; and founder and stock at Vestrum Health. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN

Aldeyra CEO and president Todd Brady shares the podcast mike with Dave McMullin, the former Shire executive who recently joined as senior vice president of corporate development and strategy. Together, the pair discuss the company’s positive Phase II test results for topical ocular reproxalap in patients with dry eye disease. They also speak about Aldeyra’s promising pipeline.

On this week’s BioTech Nation, Aaron Horowitz and Hannah Chung, Co-Founders of Sproutel and Designers of My Special AFLAC Duck, for children with cancer. Then on Tech Nation Health, Dr. Todd Brady, CEO of Aldeyra describes their work on a disease which affects one-third of people. It led to a new drug helping patients with a very rare disease - Sjögren (“Show-gren”) -Larsson Syndrome

On this week’s Tech Nation Health, Dr. Todd Brady, CEO of Aldeyra describes their work on a disease which affects one-third of people. It led to a new drug helping patients with a very rare disease - Sjögren (“Show-gren”) -Larsson Syndrome

On this week's Tech Nation, Aaron Horowitz and Hannah Chung, Co-Founders of Sproutel and Designers of My Special AFLAC Duck, for children with cancer. Then on Tech Nation Health, Dr. Todd Brady, CEO of Aldeyra describes their work on a disease which affects one-third of people. It led to a new drug helping patients with a very rare disease - Sjögren (“Show-gren”) -Larsson Syndrome

Once a VC, Todd Barry decided to assume the CEO and president post of Aldeyra, a start-up with a promising – and potentially far-reaching – technology for treating ocular and other diseases.